Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Mitochondrial electron transport chain complex I Q-site is the specific binding pocket within NADH:ubiquinone oxidoreductase where ubiquinone (Coenzyme Q10) undergoes reduction to ubiquinol. This site is structurally formed by the interface of several subunits, including the mitochondrially encoded ND1 and the nuclear-encoded NDUFS2 and NDUFS7 subunits [Fiedorczuk et al., 2016, Nature]. Its primary biological function is to facilitate the transfer of electrons from the terminal iron-sulfur cluster (N2) to the quinone pool, a process coupled to the pumping of four protons across the inner mitochondrial membrane to drive ATP synthesis [Hirst, 2013, Annual Review of Biochemistry]. Dysregulation or genetic mutations at this site are central to the pathogenesis of mitochondrial diseases such as Leber Hereditary Optic Neuropathy (LHON) and Leigh syndrome [Chinnery, 2015, GeneReviews]. Furthermore, the Q-site is a significant source of reactive oxygen species (ROS) when electron flow is impeded, contributing to neurodegenerative conditions like Parkinson's disease [Vila et al., 2008, Trends in Molecular Medicine]. Many small molecules, including the pesticide rotenone and the anti-diabetic drug metformin, interact with this site to modulate mitochondrial respiration and cellular energy sensing [Bridges et al., 2014, PMID: 25043038].
Inhibition of electron transfer from the terminal iron-sulfur cluster (N2) to ubiquinone, which prevents the reduction of Coenzyme Q and disrupts the proton gradient required for ATP synthesis [Hirst, 2013, Annual Review of Biochemistry].
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NADH:ubiquinone oxidoreductase (Complex I) ubiquinone-binding site (Q-site) (Complex I Q-site).